News

Velocity Clinical Research announces it has acquired two multi-site companies, VitaLink Research and the National Research Institute, for an undisclosed amount. The double acquisition adds 11 sites to Velocity’s existing 18, making it the largest fully integrated site management...

Anaqua, the leading innovation and intellectual property management technology provider, announced that global medical products and technologies group ConvaTec will use Anaqua’s AQX platform to help more effectively manage their valuable patent and trademark portfolios. The agreement further strengthens Anaqua’s...

Pfizer Inc. and BioNTech SE announced results from a Phase 2/3 trial showing a favorable safety profile and robust neutralizing antibody responses in children 5 to 11 years of age using a two-dose regimen of 10 µg administered 21...

Samsung Bioepis Co., Ltd. and Biogen Inc. announced that the U.S. FDA has approved BYOOVIZ (ranibizumab-nuna), a biosimilar referencing LUCENTIS® (ranibizumab)i , for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO),...

Valneva SE, a specialty vaccine company, announced that it has completed recruitment of the initial cohort of elderly participants in Valneva’s Phase 3 trial, VLA2001-304, of its inactivated COVID-19 vaccine candidate, VLA2001. 300 volunteers aged 56 years and older have...

Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, announced the successful completion of its Post Marketing Surveillance (PMS) study on Favipiravir (FabiFlu®) in India. The PMS study commenced in July 2020 to evaluate the safety and efficacy of Favipiravir...

The U.S. FDAhas expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered together to include post-exposure prophylaxis (PEP) in certain individuals for the prevention of SARS-CoV-2 infection, Eli Lilly and Company (NYSE: LLY)...